Induction Immunosuppressive Therapies in Renal Transplantation

Steven Gabardi, Pharm.D., BCPS; Spencer T. Martin, Pharm.D., BCPS; Keri L. Roberts, Pharm.D.; Monica Grafals, M.D.


Am J Health Syst Pharm. 2011;68(3):211-218. 

In This Article


It is well accepted that induction therapy in renal transplantation improves short-term outcomes in terms of improvement in acute cellular rejection after transplantation. Its use in practice depends entirely on clinician and institutional preferences and their evaluation of the potential risks versus benefits of these agents. Currently, antithymocyte globulin (rabbit) is one the most potent immunosuppressives available and is the most commonly used induction agent in renal transplantation in the United States. Basiliximab is not as potent but has a much more favorable adverse-effect profile compared with antithymocyte globulin (rabbit) and is most commonly used in low-risk patients. Each agent discussed in this article presents both challenges and benefits in clinical care. Unfortunately, there is no standard immunosuppression regimen that is considered the most effective; therefore, the agent of choice must be determined by individual clinicians and institutions.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.